SSY Group (HKG:2005) said that China's National Medical Products Administration approved two of its products, Vonoprazan Fumarate and Dronedarone Hydrochloride, for registration to become a bulk drug for preparations on the market, according to a Monday filing with the Hong Kong bourse.
Vonoprazan Fumarate is mainly used to treat reflux esophagitis, while Dronedarone Hydrochloride is an antiarrhythmic drug, the filing added.